Veeva MedTech Empowers Medtech Companies to Streamline Trials
Veeva MedTech's Impact on Clinical Trials
In a remarkable shift, more than 50 medtech companies, including 11 of the top 20, are now utilizing Veeva's clinical applications. This marks a significant step towards enhanced efficiency and speed within the industry.
Adoption of Veeva Solutions
Veeva Systems, a renowned player in cloud software for life sciences, has announced that these medtechs have adopted the Veeva Clinical Platform to streamline their medical device and diagnostics studies. Given the increasing complexity of regulatory requirements and fast-paced market changes, companies are transitioning from outdated legacy systems to Veeva's modern, connected applications, which offer greater flexibility and compliance.
Benefits of Veeva Clinical Platform
The scalable nature of Veeva's clinical applications enables medical device and diagnostics trials to flourish while adhering to strict local, regional, and global regulations. Organizations large and small are experiencing transformative results, with many achieving substantial efficiency gains. For instance, certain customers have reported 50% faster study setup times through Veeva EDC and an impressive 80% reduction in duplicate trial documents by using Veeva eTMF.
Industry Praises for Veeva MedTech
Kevin Liang, Veeva MedTech's vice president of clinical strategy, expresses enthusiasm for the company's collaboration with industry leaders. He emphasizes how Veeva's solutions promote effective study execution, foster collaboration, and stimulate innovation, ultimately expediting the delivery of life-saving products to patients.
Testimonials Highlighting Efficiency
Various professionals within the medtech industry are sharing their success stories related to Veeva. Leianne Ebert, head of clinical data operations at Alcon, states that collaboration with Veeva led to substantial advancements in global library standards, achieving 50% standardization in just one year, thus enhancing compliance across operations.
Similarly, Kimberly Dorsch, vice president of global clinical affairs at LifeNet Health, praises Veeva for facilitating a consistent approach to study data collection, which is crucial for regulatory acceptance across diverse study types.
Matt Christensen, senior vice president at Smith+Nephew, shares impressive statistics as well; he notes that since implementing Veeva eTMF, their quality control time has decreased by over 90%, further streamlining document creation.
About Veeva Systems
Veeva is recognized as the global leader in cloud software solutions specifically designed for the life sciences sector. With a strong commitment to innovation, product excellence, and the success of their customers, Veeva caters to over 1,000 clients, ranging from major biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva strives to ensure that the interests of all stakeholders—including customers, employees, and industry partners—are balanced.
Frequently Asked Questions
What advantages do medtech companies gain from Veeva?
Many medtech companies achieve faster study builds, improved compliance, and streamlined data handling by using Veeva's clinical applications.
How does Veeva support regulatory compliance?
Veeva's clinical solutions facilitate compliance with stringent local and global regulations, providing consistent data collection standards across various study types.
Can smaller medtech firms benefit from Veeva's platform?
Absolutely! Veeva's applications are suitable for firms of all sizes, offering tailored support to enhance efficiency and compliance.
What impact has Veeva had on study execution?
Veeva has significantly improved study execution speed and efficiency, helping medtechs to bring life-saving products to market faster.
How can I learn more about Veeva Clinical Platform applications?
A wealth of information on Veeva's Clinical Platform can be found on their official site, showcasing their medtech solutions.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.